Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Cardiotoxicity 14Breast Neoplasms 11Lymphoma, Non-Hodgkin 5Neoplasms 4Lymphoma 4Heart Failure 4Prostatic Neoplasms 2Multiple Myeloma 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia 2Heart Diseases 2Cardiovascular Diseases 2Burkitt Lymphoma 2Ventricular Dysfunction, Left 1Ventricular Dysfunction 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Radiation Injuries 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Obesity 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Metastatic Solid Tumors 1Metabolic Syndrome 1Mesothelioma 1Memory Disorders 1

Interventions

Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 43fludarabine phosphate 42Mycophenolic Acid 30Whole-Body Irradiation 27Cyclosporine 27Busulfan 26Tacrolimus 23Antilymphocyte Serum 23Methotrexate 20Etoposide 20romidepsin 19Filgrastim 19Melphalan 16Radiotherapy 15Flow Cytometry 15Vorinostat 13Methylprednisolone 13Brentuximab Vedotin 13Lenalidomide 12Bexarotene 12mogamulizumab 11Psychiatric Rehabilitation 11Bortezomib 11Therapeutics 10Rituximab 10Gemcitabine 10fludarabine 9Polymerase Chain Reaction 9Biopsy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × Echocardiography × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡